FMP
TC Biopharm (Holdings) Plc
TCBP
NASDAQ
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
1.35 USD
0.02 (1.48%)
About
ceo
Mr. Bryan L. Kobel
sector
Healthcare
industry
Biotechnology
website
https://www.tcbiopharm.com
exchange
NASDAQ
Description
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
CIK
0001872812
ISIN
US87807D4007
CUSIP
87807D103
Address
Maxim 1
Phone
44 14 1433 7557
Country
GB
Employee
41
IPO Date
Feb 11, 2022
Key Executives
